Post Essential Thrombocythaemia Myelofibrosis

Also known as: Post- Essential Thrombocythemia Myelofibrosis / Post Essential Thrombocythemia-myelofibrosis / Post Essential Thrombocythemia Myelofibrosis / Post-Essential Thrombocythemia Myelofibrosis / Myelofibrosis due to and following essential thrombocythemia (disorder) / Myelosis non-leukemic / Agnogenic myeloid metaplasia / Myelofibrosis (disorder) / Myelofibrosis / (Other blood diseases NOS) or (myelofibrosis) / Myelosis-non-leukaemic / Myelosis non-leukaemic / Myelosis nonleukemic / Myelosclerosis / Myelofibrosis NOS

DrugDrug NameDrug Description
DB08877RuxolitinibA kinase inhibitor used to treat various types of myelofibrosis, polycythemia vera in patients who have not responded to or cannot tolerate hydroxyurea, and to treat graft-versus-host disease in cases that are refractory to steroid treatment.
DrugDrug NamePhaseStatusCount
DB01262Decitabine1Withdrawn1
DB12638PU-H711Terminated1
DB06603Panobinostat1Completed1
DB08877Ruxolitinib1Completed1
DB08877Ruxolitinib1Terminated1
DB16322Sabatolimab1Withdrawn1
DB14892Spartalizumab1Withdrawn1
DB11763Momelotinib1 / 2Completed2
DB12784NS-0181 / 2Completed1
DB08877Ruxolitinib1 / 2Recruiting1
DB11763Momelotinib2Completed2
DB12784NS-0182Not Yet Recruiting1
DB14852PRM-1512Completed1
DB11697Pacritinib2Completed1
DB09037Pembrolizumab2Completed1
DB08877Ruxolitinib2Completed3
DB08877Ruxolitinib2Terminated1
DB11942Selinexor2Recruiting1
DB01406Danazol3Active Not Recruiting1
DB01406Danazol3Recruiting1
DB01005Hydroxyurea3Recruiting1
DB11763Momelotinib3Active Not Recruiting1
DB11763Momelotinib3Completed1
DB11697Pacritinib3Recruiting1
DB11697Pacritinib3Terminated2
DB14867Parsaclisib3Not Yet Recruiting1
DB14867Parsaclisib3Recruiting3
DB08877Ruxolitinib3Completed1
DB08877Ruxolitinib3Not Yet Recruiting1
DB08877Ruxolitinib3Recruiting5
DB06603Panobinostat4Recruiting1
DB08877Ruxolitinib4Recruiting1